Esperante D, Flisser A, Mendlovic F
Front Immunol. 2023; 14:1101390.
PMID: 36993959
PMC: 10040973.
DOI: 10.3389/fimmu.2023.1101390.
Immanuel T, Li J, Green T, Bogdanova A, Kalev-Zylinska M
Front Oncol. 2022; 12:1010506.
PMID: 36330491
PMC: 9623116.
DOI: 10.3389/fonc.2022.1010506.
Guijarro-Hernandez A, Vizmanos J
Cancers (Basel). 2021; 13(5).
PMID: 33652860
PMC: 7956519.
DOI: 10.3390/cancers13050984.
Prins D, Gonzalez Arias C, Klampfl T, Grinfeld J, Green A
Hemasphere. 2020; 4(1):e333.
PMID: 32382708
PMC: 7000472.
DOI: 10.1097/HS9.0000000000000333.
Hearn J, Green T, Chopra M, Nursalim Y, Ladvanszky L, Knowlton N
Thromb Haemost. 2020; 120(4):671-686.
PMID: 32289863
PMC: 7286128.
DOI: 10.1055/s-0040-1708483.
Somatic mutations and cell identity linked by Genotyping of Transcriptomes.
Nam A, Kim K, Chaligne R, Izzo F, Ang C, Taylor J
Nature. 2019; 571(7765):355-360.
PMID: 31270458
PMC: 6782071.
DOI: 10.1038/s41586-019-1367-0.
-methyl-d-aspartate receptor mediated calcium influx supports in vitro differentiation of normal mouse megakaryocytes but proliferation of leukemic cell lines.
Kamal T, Green T, Hearn J, Josefsson E, Morel-Kopp M, Ward C
Res Pract Thromb Haemost. 2018; 2(1):125-138.
PMID: 30046713
PMC: 5974914.
DOI: 10.1002/rth2.12068.
Calcium-Binding Proteins with Disordered Structure and Their Role in Secretion, Storage, and Cellular Signaling.
Grzybowska E
Biomolecules. 2018; 8(2).
PMID: 29921816
PMC: 6022996.
DOI: 10.3390/biom8020042.
Calreticulin: Challenges Posed by the Intrinsically Disordered Nature of Calreticulin to the Study of Its Function.
Varricchio L, Falchi M, DallOra M, de Benedittis C, Ruggeri A, Uversky V
Front Cell Dev Biol. 2017; 5:96.
PMID: 29218307
PMC: 5703715.
DOI: 10.3389/fcell.2017.00096.
The Calreticulin control of human stress erythropoiesis is impaired by JAK2V617F in polycythemia vera.
Falchi M, Varricchio L, Martelli F, Marra M, Picconi O, Tafuri A
Exp Hematol. 2017; 50:53-76.
PMID: 28232234
PMC: 5779852.
DOI: 10.1016/j.exphem.2017.02.001.
Calreticulin (CALR) mutation in myeloproliferative neoplasms (MPNs).
Luo W, Yu Z
Stem Cell Investig. 2016; 2:16.
PMID: 27358884
PMC: 4923638.
DOI: 10.3978/j.issn.2306-9759.2015.08.01.
Mutant calreticulin-expressing cells induce monocyte hyperreactivity through a paracrine mechanism.
Garbati M, Welgan C, Landefeld S, Newell L, Agarwal A, Dunlap J
Am J Hematol. 2015; 91(2):211-9.
PMID: 26573090
PMC: 4877170.
DOI: 10.1002/ajh.24245.
Differential clinical effects of different mutation subtypes in CALR-mutant myeloproliferative neoplasms.
Pietra D, Rumi E, Ferretti V, Di Buduo C, Milanesi C, Cavalloni C
Leukemia. 2015; 30(2):431-8.
PMID: 26449662
PMC: 4740452.
DOI: 10.1038/leu.2015.277.
Frequent CALR exon 9 alterations in JAK2 V617F-mutated essential thrombocythemia detected by high-resolution melting analysis.
Lim K, Chang Y, Gon-Shen Chen C, Lin H, Wang W, Chiang Y
Blood Cancer J. 2015; 5:e295.
PMID: 25794131
PMC: 4382662.
DOI: 10.1038/bcj.2015.21.
Bioinformatic analyses of CALR mutations in myeloproliferative neoplasms support a role in signaling.
Eder-Azanza L, Navarro D, Aranaz P, Novo F, Cross N, Vizmanos J
Leukemia. 2014; 28(10):2106-9.
PMID: 24919806
DOI: 10.1038/leu.2014.190.